{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:52:50Z","timestamp":1790409170511,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R35CA263817"],"award-info":[{"award-number":["R35CA263817"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Early therapeutic intervention in high-risk smoldering multiple myeloma (HR-SMM) has shown benefits, however, no studies have assessed whether biochemical progression or response depth predicts long-term outcomes. The single-arm I-PRISM phase II trial (NCT02916771) evaluated ixazomib, lenalidomide, and dexamethasone in 55 patients with HR-SMM. The primary endpoint, median progression-free survival (PFS), was not reached (NR) (95% CI: 57.7\u2013NR, median follow-up 50 months). The secondary endpoint, biochemical PFS, was 48.6 months (95% CI: 39.9\u2013NR) and coincided with or preceded SLiM-CRAB in eight patients. For additional secondary objectives, the overall response rate was 93% with 31% achieving complete response (CR) and 45% very good partial response (VGPR) or better. CR correlated strongly with the absence of SLiM-CRAB and biochemical progression. MRD-negativity (10<jats:sup>-5<\/jats:sup> sensitivity) predicted a 5-year biochemical PFS of 100% versus 40% in MRD-positive patients (p\u2009=\u20090.051), demonstrating that deep responses significantly improve time to progression. Exploratory single-cell RNA sequencing linked tumor MHC class I expression to proteasome inhibitor response, and a lower proportion of GZMB+\u2009T cells within clonally expanded CD8+\u2009T cells associated with suboptimal outcomes.<\/jats:p>","DOI":"10.1038\/s41467-024-55308-5","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T08:37:43Z","timestamp":1735893463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Omar","family":"Nadeem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8230-5726","authenticated-orcid":false,"given":"Michelle P.","family":"Aranha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-5288","authenticated-orcid":false,"given":"Robert","family":"Redd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-3502","authenticated-orcid":false,"given":"Michael","family":"Timonian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4225-135X","authenticated-orcid":false,"given":"Sophie","family":"Magidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Lightbody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-7294","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Alberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bertamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit K.","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"El-Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4652-5449","authenticated-orcid":false,"given":"Mark","family":"Bustoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romanos","family":"Sklavenitis-Pistofidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"55308_CR1","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"55308_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 10, 102 (2020).","journal-title":"Blood Cancer J."},{"key":"55308_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri, A. et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111, 785\u2013789 (2008).","journal-title":"Blood"},{"key":"55308_CR4","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E Perez-Persona","year":"2007","unstructured":"Perez-Persona, E. et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110, 2586\u20132592 (2007).","journal-title":"Blood"},{"key":"55308_CR5","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar, S. V., Landgren, O. & Mateos, M. V. Smoldering multiple myeloma. Blood 125, 3069\u20133075 (2015).","journal-title":"Blood"},{"key":"55308_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 8, 59 (2018).","journal-title":"Blood Cancer J."},{"key":"55308_CR7","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","volume":"10","author":"A Cowan","year":"2023","unstructured":"Cowan, A. et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 10, e203\u2013e212 (2023).","journal-title":"Lancet Haematol."},{"key":"55308_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438\u2013447 (2013).","journal-title":"N. Engl. J. Med."},{"key":"55308_CR9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126\u20131137 (2020).","journal-title":"J. Clin. Oncol."},{"key":"55308_CR10","doi-asserted-by":"crossref","unstructured":"Mateos, M.-V. et al. Lenalidomide-dexamethasone vs. observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study. Eur. J. Cancer 174, 243\u2013250 (2022).","DOI":"10.1016\/j.ejca.2022.07.030"},{"key":"55308_CR11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood.2020009752","volume":"137","author":"AM Goodman","year":"2021","unstructured":"Goodman, A. M., Kim, M. S. & Prasad, V. Persistent challenges with treating multiple myeloma early. Blood 137, 456\u2013458 (2021).","journal-title":"Blood"},{"key":"55308_CR12","doi-asserted-by":"publisher","unstructured":"Avet-Loiseau, H. & Bahlis, N. J. Smoldering multiple myeloma: taking the narrow over the wide path? Blood. https:\/\/doi.org\/10.1182\/blood.2024023880 (2024).","DOI":"10.1182\/blood.2024023880"},{"key":"55308_CR13","doi-asserted-by":"publisher","unstructured":"Ghobrial, I. M. et al. Round table discussion on optimal clinical trial design in precursor multiple myeloma. Blood Cancer Discov. OF1-OF7. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-24-0022 (2024).","DOI":"10.1158\/2643-3230.Bcd-24-0022"},{"key":"55308_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1182\/blood-2019-125204","volume":"134","author":"LJ Mateos MV","year":"2019","unstructured":"Mateos MV, L. J. et al. Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd. Blood 134, 781 (2019).","journal-title":"Blood"},{"key":"55308_CR15","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","volume":"7","author":"D Kazandjian","year":"2021","unstructured":"Kazandjian, D. et al. Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial. JAMA Oncol. 7, 1678\u20131685 (2021).","journal-title":"JAMA Oncol."},{"key":"55308_CR16","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","volume":"40","author":"R Sklavenitis-Pistofidis","year":"2022","unstructured":"Sklavenitis-Pistofidis, R. et al. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell 40, 1358\u20131373.e1358 (2022).","journal-title":"Cancer Cell"},{"key":"55308_CR17","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood-2022-168930","volume":"140","author":"SK Kumar","year":"2022","unstructured":"Kumar, S. K. et al. Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple myeloma-results of the ascent trial. Blood 140, 1830\u20131832 (2022).","journal-title":"Blood"},{"key":"55308_CR18","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.20.00437","volume":"38","author":"M Bustoros","year":"2020","unstructured":"Bustoros, M. et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J. Clin. Oncol. 38, 2380\u20132389 (2020).","journal-title":"J. Clin. Oncol."},{"key":"55308_CR19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","volume":"34","author":"K Misund","year":"2020","unstructured":"Misund, K. et al. MYC dysregulation in the progression of multiple myeloma. Leukemia 34, 322\u2013326 (2020).","journal-title":"Leukemia"},{"key":"55308_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20524-2","volume":"12","author":"EM Boyle","year":"2021","unstructured":"Boyle, E. M. et al. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat. Commun. 12, 293 (2021).","journal-title":"Nat. Commun."},{"key":"55308_CR21","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie, B. G. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006).","journal-title":"Leukemia"},{"key":"55308_CR22","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"55308_CR23","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.1200\/EDBK_159009","volume":"35","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar, S. V. Updated diagnostic criteria and staging system for multiple myeloma. Am. Soc. Clin. Oncol. Educ. Book 35, e418\u2013e423 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"55308_CR24","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1200\/JCO.2019.37.15_suppl.8001","volume":"37","author":"S Lonial","year":"2019","unstructured":"Lonial, S. et al. E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. J. Clin. Oncol. 37, 8001\u20138001 (2019).","journal-title":"J. Clin. Oncol."},{"key":"55308_CR25","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi, N. C. et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 4, 5988\u20135999 (2020).","journal-title":"Blood Adv."},{"key":"55308_CR26","doi-asserted-by":"publisher","first-page":"e0267979","DOI":"10.1371\/journal.pone.0267979","volume":"17","author":"P Daniele","year":"2022","unstructured":"Daniele, P. et al. Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. PLoS ONE 17, e0267979 (2022).","journal-title":"PLoS ONE"},{"key":"55308_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","volume":"2","author":"A Gulla","year":"2021","unstructured":"Gulla, A. et al. Bortezomib induces anti\u2013multiple myeloma immune response mediated by cGAS\/STING pathway activation. Blood Cancer Discov. 2, 468\u2013483 (2021).","journal-title":"Blood Cancer Discov."},{"key":"55308_CR28","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood.2020008787","volume":"137","author":"T Facon","year":"2021","unstructured":"Facon, T. et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 137, 3616\u20133628 (2021).","journal-title":"Blood"},{"key":"55308_CR29","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 374, 1621\u20131634 (2016).","journal-title":"N. Engl. J. Med."},{"key":"55308_CR30","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","volume":"2","author":"V Wu","year":"2018","unstructured":"Wu, V. et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2, 1470\u20131479 (2018).","journal-title":"Blood Adv."},{"key":"55308_CR31","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132, 2456\u20132464 (2018).","journal-title":"Blood"},{"key":"55308_CR32","doi-asserted-by":"publisher","unstructured":"El-Khoury, H. et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. https:\/\/doi.org\/10.1016\/s2352-3026(22)00069-2 (2022).","DOI":"10.1016\/s2352-3026(22)00069-2"},{"key":"55308_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2159-8290.CD-22-0482","volume":"13","author":"AK Dutta","year":"2023","unstructured":"Dutta, A. K. et al. MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology. Cancer Discov. 13, 348\u2013363 (2023).","journal-title":"Cancer Discov."},{"key":"55308_CR34","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv preprint arXiv:1303.3997 (2013)."},{"key":"55308_CR35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"55308_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"55308_CR37","doi-asserted-by":"publisher","unstructured":"Morton, L. M. et al. Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science 372. https:\/\/doi.org\/10.1126\/science.abg2538 (2021).","DOI":"10.1126\/science.abg2538"},{"key":"55308_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GX Zheng","year":"2017","unstructured":"Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).","journal-title":"Nat. Commun."},{"key":"55308_CR39","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281\u2013291.e289 (2019).","journal-title":"Cell Syst."},{"key":"55308_CR40","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/bioinformatics\/btz698","volume":"36","author":"AS Bais","year":"2020","unstructured":"Bais, A. S. & Kostka, D. scds: computational annotation of doublets in single-cell RNA sequencing data. Bioinformatics 36, 1150\u20131158 (2020).","journal-title":"Bioinformatics"},{"key":"55308_CR41","doi-asserted-by":"publisher","first-page":"979","DOI":"10.12688\/f1000research.73600.1","volume":"10","author":"PL Germain","year":"2021","unstructured":"Germain, P. L., Lun, A., Garcia Meixide, C., Macnair, W. & Robinson, M. D. Doublet identification in single-cell sequencing data using scDblFinder. F1000Res 10, 979 (2021).","journal-title":"F1000Res"},{"key":"55308_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."},{"key":"55308_CR43","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"55308_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41587-022-01468-y","volume":"41","author":"T Gao","year":"2023","unstructured":"Gao, T. et al. Haplotype-aware analysis of somatic copy number variations from single-cell transcriptomes. Nat. Biotechnol. 41, 417\u2013426 (2023).","journal-title":"Nat. Biotechnol."},{"key":"55308_CR45","doi-asserted-by":"crossref","unstructured":"Therneau, T. M., Grambsch, P. M., Therneau, T. M. & Grambsch, P. M. The Cox model (Springer, 2000).","DOI":"10.1007\/978-1-4757-3294-8_3"},{"key":"55308_CR46","first-page":"2014","volume":"2","author":"T Therneau","year":"2015","unstructured":"Therneau, T. A package for survival analysis in S. R. package version 2, 2014 (2015).","journal-title":"R. package version"},{"key":"55308_CR47","first-page":"1","volume":"22","author":"M Gamer","year":"2012","unstructured":"Gamer, M., Lemon, J., Gamer, M. M., Robinson, A. & Kendall\u2019s, W. Package \u2018irr\u2019. Var. Coeff. Interrater Reliab. Agreem. 22, 1\u201332 (2012).","journal-title":"Var. Coeff. Interrater Reliab. Agreem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55308-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:01:36Z","timestamp":1735894896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55308-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55308"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55308-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.N. reports research support from Takeda and Janssen; advisory board participation for Bristol Myers Squibb, Janssen, Sanofi, Takeda, and GPCR therapeutics; and honorarium from Pfizer. M.B. reports consultancy for Janssen, BMS, Takeda, Epizyme, Karyopharm, Menarini Biosystems, and Adaptive. G.B. reports consultancy for Prothena. E.O. reports advisory board participation and\/or honoraria from Janssen, BMS, Sanofi, Pfizer, Exact; consulting for Takeda; and steering committee participation with Natera. K.A. reports consultancy for AstraZeneca, Janssen, and Pfizer; and board participation and stock options for Dynamic Cell Therapies, C4 Therapeutics, Next RNA, Oncopep, Starton, and Window. P.G.R. reports advisory board participation or consulting for Celgene (BMS), GSK, Karyopharm, Oncopeptides, Regeneron, Sanofi, and Takeda; and research grants from Oncopeptides and Karyopharm. R.S.P. is a co-founder, equity holder, and consultant for PreDICTA Bioscience. I.M.G.: Consulting\/Advisory role: AbbVie, Adaptive, Amgen, Aptitude Health, Bristol Myers Squibb, GlaxoSmithKline, Huron Consulting, Janssen, Menarini Silicon Biosystems, Oncopeptides, Pfizer, Sanofi, Sognef, Takeda, Binding Site a part of Thermo Fischer Scientific, Window Therapeutics, and 10X Genomics; speaker fees from Vor Biopharma and Veeva Systems, Inc., and is a co-founder of PreDICTA Bioscience. I.M.G.\u2019s spouse is the CMO and an equity holder of Disc Medicine. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"One or more of the authors of this paper self-identifies as an underrepresented ethnic and\/or gender minority in science. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community. We support inclusive, diverse, and equitable conduct of research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Inclusion and ethics"}}],"article-number":"358"}}